IPO roundup: Mirna, RainDance

Cancer company Mirna Therapeutics Inc. (Austin, Texas) filed to go public, while genetic research tool play RainDance Technologies Inc. (Billerica, Mass.) pulled its IPO.

Mirna proposed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup; Leerink; Oppenheimer; and Cantor Fitzgerald. Mirna's lead candidate MRX34 is in a Phase I trial to treat hepatocellular carcinoma (HCC), other solid tumors and hematological malignancies. MRX34 is a synthetic mimic of miR-34, a naturally occurring tumor suppressor, formulated with lipid-based nanoparticles. ...